top of page

CureLab Veterinary
CureLab Veterinary Common Stock 1
P62 plasmid technology poised to revolutionize cancer treatment in dogs and cats
There is a newer open investment round for this company - click here to view
Our take:
If the maximum offering is raised, more than 40% will go towards compensation for managers. The technology is licensed from a different company with the same management. In the press release announcing this new company, the company said they expected to be profitable in 3 years, but the crowdfunding campaign says that it doesn't expect sales to start for at least 24-36 months.
Sign up to receive weekly deal alerts and top news
Round Performance

Amount Raised
[]

Average Investment
[]

Average Per Day
[]

# of Investors
[]
Investors vs. Capital Raised
Investment Type
Common Stock
Round Valuation
$32,653,950
Minimum Investment
$120
Price Per Share
$30
Investment Details
Early Bird Perks
Perk description | Perk level (dollars) | Perk level (days) |
---|
Loading...
Similar Investments
bottom of page